Unpacking the Benefits of Sacubitril Valsartan: A Comprehensive Guide

Are you a medical professional looking to stay up-to-date on the latest treatments for heart failure? Look no further than sacubitril valsartan. This revolutionary drug has been shown to significantly reduce hospitalizations and mortality rates in patients with heart failure with reduced ejection fraction. In this comprehensive guide, we'll unpack the benefits of sacubitril valsartan and explore its potential as a game-changing treatment option for your patients. Don't miss out on this exciting breakthrough – read on to learn more!

What is Sacubitril Valsartan?

Sacubitril valsartan ( brand name: Entresto) is a medication used to treat heart failure. It is a combination of two drugs: sacubitril (also called neprilysin inhibitor or NEPI) and valsartan ( an angiotensin II receptor blocker or ARB).  Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs. This can happen because the heart muscle has become weaker, usually due to a heart attack. When this happens, fluid can build up in the lungs and other parts of the body. The sacubitril part of Entresto works by inhibiting neprilysin, an enzyme that breaks down many different hormones, including natriuretic peptides. Natriuretic peptides are hormones that help to regulate blood pressure and fluid balance in the body. They also play a role in clearing away excess salt and water from the body. Inhibiting neprilysin leads to increased levels of these helpful hormones in the body, which helps to improve blood pressure and reduce fluid retention. The valsartan part of Entresto works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow. This narrowing can lead to an increase in blood pressure. 

How does sacubitril valsartan work?

The angiotensin-converting enzyme inhibitor (ACEI) sacubitril (Entresto, Novartis) is a prodrug that is rapidly metabolized to its active moiety, LBQ657. LBQ657 selectively inhibits neprilysin, also known as membrane metalloendopeptidase (NEP). Inhibition of NEP results in increased concentrations of endogenous natriuretic peptides, which leads to vasodilation and reduction in preload and afterload. The decrease in cardiac workload reduces myocardial oxygen demand and helps to improve symptoms in patients with heart failure. Sacubitril valsartan is indicated for the treatment of symptomatic heart failure in adults with reduced ejection fraction. It should be used in conjunction with an ACE inhibitor or angiotensin receptor blocker (ARB) unless contraindicated. The recommended starting dose is 97/103 mg twice daily, with titration to the maximum tolerated dose of sacubitril/valsartan (200 mg/160 mg twice daily).

What are the benefits of sacubitril valsartan?

Sacubitril valsartan (Entresto) is a novel angiotensin receptor-neprilysin inhibitor (ARNI) indicated for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). The active moiety, sacubitril, is a prodrug that is metabolized to LBQ657, its active neprilysin inhibitor. Valsartan is an angiotensin II receptor blocker (ARB). The co-administration of sacubitril/valsartan results in similar blood pressure lowering as valsartan monotherapy; however, no head-to-head trials are comparing the two agents. Sacubitril/valsartan was studied in the PARADIGM-HF trial, which enrolled 8442 patients with HFrEF and a left ventricular ejection fraction (LVEF) of 40% or less who were either on maximally tolerated doses of an ACE inhibitor or ARB with beta-blockers or were unable to tolerate these agents. The primary endpoint was a composite of cardiovascular death or hospitalization for heart failure. After a median follow-up period of 27 months, sacubitril/valsartan significantly reduced the risk of the primary endpoint compared to enalapril, with a hazard ratio of 0.80 (95% CI: 0.73-0.87; p<0.001).

What are the side effects of sacubitril valsartan?

The most common side effects of sacubitril valsartan are headache, diarrhea, and dizziness. Less common side effects include fatigue, nausea, and abdominal pain. Sacubitril valsartan can cause a drop in blood pressure, which may cause dizziness or fainting. If patient's experience these symptoms, be sure to drink plenty of fluids and avoid standing for long periods of time. If patient's have any kidney problems, sacubitril valsartan can increase risk of kidney failure. The medical professionals should check about kidney problems before starting this medication. This medication can also cause an increase in potassium levels in the blood. If patient's  have high blood pressure or heart failure, this could make condition worse. 

Conclusion

In conclusion, sacubitril valsartan is a highly effective drug with many potential benefits for patients. While it’s important to note that the evidence of clinical efficacy is still relatively limited and there are some cautions surrounding its use, it remains an attractive option for physicians looking to help their patients manage heart failure. We hope this guide has given you all the necessary information on sacubitril valsartan so that you can make informed decisions about prescribing it for your patients.